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Abstract
© 2015 Park-media, Ltd. B cells play a crucial role in the development and pathogenesis of
systemic  and  organ-specific  autoimmune  diseases.  Autoreactive  B  cells  not  only  produce
antibodies, but also secrete pro-inflammatory cytokines and present specific autoantigens to T
cells. The treatment of autoimmune diseases via the elimination of the majority of B cells using
the monoclonal  anti-CD19/20 antibody (Rituximab)  causes systemic side effects  and,  thus,
requires a major revision. Therapeutic intervention directed towards selective elimination of
pathogenic  autoreactive  B  cells  has  the potential  to  become a  universal  approach to  the
treatment  of  various  autoimmune  abnormalities.  Here,  we  developed  a  recombinant
immunotoxin based on the immunodominant peptide of the myelin basic protein (MBP), fused to
the antibody Fc domain. We showed that the obtained immunotoxin provides selective in vivo
elimination of autoreactive B cells in mice with experimental autoimmune encephalomyelitis.
The proposed conception may be further used for the development of new therapeutics for a
targeted treatment of multiple sclerosis and other autoimmune disorders.
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